Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)
Protalix BioTherapeutics (PLX) posted quarterly Notes Payables of $4.1 million for Q4 2020, down 5.0% year-over-year from $4.3 million in Q1 2020, and down 4.98% quarter-over-quarter from $4.3 million in Q3 2020.
Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020) Analysis & Trends
Protalix BioTherapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $4.1 million for Q4 2020.
- In Q4 2020, Notes Payables fell 5.0% year-over-year to $4.1 million; the TTM figure through Dec 2020 stood at $4.1 million (down 5.0% YoY), while the FY2020 annual figure was $4.1 million, down 5.0% from the prior year.
- Notes Payables for Q4 2020 stood at $4.1 million, down from $4.3 million in the prior quarter.
- The five-year high for Notes Payables was $4.3 million in Q4 2019, with the low at $4.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 4.30 Mn |
| Jun 30, 2020 | 4.30 Mn |
| Mar 31, 2020 | 4.30 Mn |
| Dec 31, 2019 | 4.30 Mn |